Eleclazine

DRUG6 trials

Sponsors

Gilead Sciences

Conditions

Hypertrophic CardiomyopathyLQT2 SyndromeLong QT SyndromeLong QT Syndrome Type 3Ventricular Arrhythmia

Phase 1

Study to Evaluate the Effect of Eleclazine on QT, Safety, and Tolerability in Participants With Long QT2 Syndrome

CompletedNCT02365506

Gilead SciencesLQT2 Syndrome

Start: 2015-07-20End: 2016-06-13Updated: 2020-12-30

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function

CompletedNCT02412098

Gilead SciencesLong QT Syndrome

Start: 2015-03-19End: 2016-04-22Updated: 2019-07-29

Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function

CompletedNCT02441829

Gilead SciencesLong QT Syndrome

Start: 2015-05-31End: 2015-12-31Updated: 2015-12-22

Phase 2

Evaluating Ventricular Arrhythmia in Subjects With Implantable Cardioverter Defibrillator or Cardiac Resynchronization Therapy-Defibrillator

CompletedNCT02104583

Gilead SciencesVentricular Arrhythmia

Start: 2014-09-30End: 2016-10-31Updated: 2019-04-09

Effect of Eleclazine (GS-6615) on Exercise Capacity in Subjects With Symptomatic Hypertrophic Cardiomyopathy

TerminatedNCT02291237

Gilead SciencesHypertrophic Cardiomyopathy

Start: 2015-02-05End: 2017-02-17Updated: 2018-09-24

Phase 3

Effect of Eleclazine on Shortening of the QT Interval, Safety, and Tolerability in Adults With Long QT Syndrome Type 3

TerminatedNCT02300558

Gilead SciencesLong QT Syndrome Type 3

Start: 2014-12-17End: 2017-02-15Updated: 2018-01-12

Related Papers

Novel Approach Targeting the Complex Pathophysiology of Hypertrophic Cardiomyopathy

Circulation Heart Failure2016-02-2660 citations